M&R Capital Management Inc. Sells 269 Shares of Amgen Inc. (NASDAQ:AMGN)

M&R Capital Management Inc. lessened its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Get Rating) by 19.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,118 shares of the medical research company’s stock after selling 269 shares during the quarter. M&R Capital Management Inc.’s holdings in Amgen were worth $294,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Obermeyer Wood Investment Counsel Lllp raised its position in shares of Amgen by 1.3% in the 3rd quarter. Obermeyer Wood Investment Counsel Lllp now owns 2,959 shares of the medical research company’s stock worth $667,000 after purchasing an additional 38 shares during the last quarter. Arlington Partners LLC raised its position in shares of Amgen by 1.5% in the 3rd quarter. Arlington Partners LLC now owns 2,642 shares of the medical research company’s stock worth $596,000 after purchasing an additional 39 shares during the last quarter. TCI Wealth Advisors Inc. raised its position in Amgen by 1.0% in the 3rd quarter. TCI Wealth Advisors Inc. now owns 4,057 shares of the medical research company’s stock worth $914,000 after buying an additional 39 shares during the last quarter. Bellecapital International Ltd. raised its position in Amgen by 1.3% in the 3rd quarter. Bellecapital International Ltd. now owns 3,039 shares of the medical research company’s stock worth $685,000 after buying an additional 40 shares during the last quarter. Finally, Stonebridge Capital Advisors LLC raised its position in Amgen by 5.2% in the 3rd quarter. Stonebridge Capital Advisors LLC now owns 814 shares of the medical research company’s stock worth $183,000 after buying an additional 40 shares during the last quarter. Institutional investors own 75.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on AMGN shares. SVB Leerink decreased their target price on Amgen from $282.00 to $267.00 and set a “market perform” rating for the company in a research report on Thursday, February 2nd. BMO Capital Markets decreased their target price on Amgen from $276.00 to $253.00 and set a “market perform” rating for the company in a research report on Wednesday, February 1st. Royal Bank of Canada decreased their target price on Amgen from $268.00 to $258.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 1st. Oppenheimer decreased their target price on Amgen from $312.00 to $294.00 and set an “outperform” rating for the company in a research report on Wednesday, February 1st. Finally, Barclays reduced their price target on shares of Amgen from $240.00 to $230.00 and set an “underweight” rating for the company in a research report on Wednesday, February 1st. Four equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $251.44.

Amgen Price Performance

AMGN stock traded down $4.78 during midday trading on Friday, hitting $229.79. The company’s stock had a trading volume of 7,817,122 shares, compared to its average volume of 2,561,389. Amgen Inc. has a 12 month low of $223.30 and a 12 month high of $296.67. The company has a quick ratio of 1.10, a current ratio of 1.41 and a debt-to-equity ratio of 10.20. The firm has a market capitalization of $122.70 billion, a price-to-earnings ratio of 18.98, a price-to-earnings-growth ratio of 1.86 and a beta of 0.65. The company has a 50 day moving average of $245.91 and a two-hundred day moving average of $254.71.

Amgen (NASDAQ:AMGN – Get Rating) last issued its quarterly earnings data on Tuesday, February 7th. The medical research company reported $4.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.04 by $0.05. The business had revenue of $6.84 billion for the quarter, compared to analysts’ expectations of $6.77 billion. Amgen had a return on equity of 359.47% and a net margin of 24.89%. The company’s revenue for the quarter was down .1% on a year-over-year basis. During the same period in the prior year, the firm earned $4.36 EPS. On average, analysts expect that Amgen Inc. will post 17.72 EPS for the current year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 8th. Stockholders of record on Thursday, May 18th will be issued a dividend of $2.13 per share. The ex-dividend date is Wednesday, May 17th. This represents a $8.52 annualized dividend and a dividend yield of 3.71%. Amgen’s dividend payout ratio (DPR) is 70.36%.

About Amgen

(Get Rating)

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.